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Background: Abnormal immune function is often an underlying component of illness pathophysiology and symptom
presentation. Functional and phenotypic immune-related alterations may play a role in the obscure pathomechanism
of Chronic Fatigue Syndrome/Myalgic Encephalomyelitis (CFS/ME). The objective of this study was to investigate the
functional ability of innate and adaptive immune cells in moderate and severe CFS/ME patients. The 1994 Fukuda
criteria for CFS/ME were used to define CFS/ME patients. CFS/ME participants were grouped based on illness severity
with 15 moderately affected (moderate) and 12 severely affected (severe) CFS/ME patients who were age and sex
matched with 18 healthy controls. Flow cytometric protocols were used for immunological analysis of dendritic cells,
monocytes and neutrophil function as well as measures of lytic proteins and T, natural killer (NK) and B cell receptors.
Results: CFS/ME patients exhibited alterations in NK receptors and adhesion markers and receptors on CD4+T and
CD8+T cells. Moderate CFS/ME patients had increased CD8+ CD45RA effector memory T cells, SLAM expression on NK
cells, KIR2DL5+ on CD4+T cells and BTLA4+ on CD4+T central memory cells. Moderate CFS/ME patients also had
reduced CD8+T central memory LFA-1, total CD8+T KLRG1, naïve CD4+T KLRG1 and CD56dimCD16− NK cell CD2+
and CD18+CD2+. Severe CFS/ME patients had increased CD18+CD11c− in the CD56dimCD16− NK cell phenotype
and reduced NKp46 in CD56brightCD16dim NK cells.
Conclusions: This research accentuated the presence of immunological abnormalities in CFS/ME and highlighted
the importance of assessing functional parameters of both innate and adaptive immune systems in the illness.
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The innate immune system exhibits rapid effector func-
tions and acts as the first line of defence, protecting the
host cells while activating the adaptive immune system.
Natural killer (NK) cells in particular are an important
interface for the innate and adaptive immune systems;
hence, impaired function potentially leads to immuno-
logical disturbances. The presence of immunological
dysfunction may impair physiological functioning and
may play a role in disease pathogenesis [1]. NK cell dys-
regulation has been demonstrated in a number of illnesses,* Correspondence: sharni.hardcastle@hotmail.com
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unless otherwise stated.including human immunodeficiency syndrome (HIV), sys-
temic lupus erythematosus (SLE), multiple sclerosis (MS)
and Major Depressive Disorder (MDD) [2-4].
Patients with Chronic Fatigue Syndrome/Myalgic En-
cephalomyelitis (CFS/ME) exhibit reduced NK and CD8+T
cell cytotoxic activity and differences in a number of adap-
tive immune cell phenotypes [5, 6]. Significant decreases
in NK cell cytotoxic activity in CFS/ME patients who were
moderately affected by symptoms and characterised using
the Fukuda criteria for the illness have been extensively re-
ported [5, 7-23]. The reduced NK cell cytotoxic activity in
CFS/ME patients may be associated with abnormalities in
NK cell phenotypes, receptors or lytic proteins. Of the
previous CFS/ME studies, five have also found significant
differences in perforin and granzymes in NK cells of CFS/tral. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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and phenotypic components of immune cells may be play-
ing a role in the pathomechanism of CFS/ME.
CFS/ME is an enigmatic illness which has no known
pathomechanism or cause, with diagnoses based on symp-
tom specific criteria and a range of exclusions. Due to the
multifactorial and complex nature of CFS/ME, there are
often misconceptions and inconsistencies surrounding
diagnosis which highlights the importance of thorough
screening of participants in both clinical and research set-
tings. This is particularly important in determining those
with other illnesses such as major depression who may
satisfy the CFS/ME symptom specific criteria and also
demonstrate NK cell abnormalities [2]. CFS/ME is charac-
terised by persistent fatigue and a combination of symp-
toms which are often severely debilitating and the illness
also tends to vary greatly in the nature of onset and symp-
tom severity [5, 7, 27-31]. Moderate patients are mostly
able to maintain normal daily activities but may be ham-
pered by reduced mobility while severely affected CFS/ME
patients experience high levels of daily fatigue and are typ-
ically housebound [32].
Importantly, severe CFS/ME patients’ NK cell cytotoxic
activity has only been reported in three previous investiga-
tions [5, 7, 13]. Severely affected CFS/ME patients have
demonstrated significant reductions in NK cell cytotoxic
activity as well as increased NK cell receptor KIR3DL1
and enhanced plasma interleukin (IL)-4, tumour necrosis
factor (TNF)-α and interferon (IFN)-γ [7, 13]. This re-
search also suggested a correlation between low NK cell
cytotoxic activity and severity of CFS/ME, based on clin-
ical status [13]. As studies have investigated innate and
adaptive immune cells in CFS/ME patients, it appears im-
portant to further examine functional parameters such as
cell activity, receptors and adhesion molecules. Along with
NK cell and CD8+T cell aberrations [5, 7, 11, 19, 33], den-
dritic cell (DC) phenotypes have been previously abnormal
in CFS/ME patients [5] although to date no study has
assessed DC activity in the illness. Similarly, iNKT cells
are seldom examined although one study found differ-
ences in iNKT cell phenotypes in CFS/ME patients [5],
suggesting the possibility of iNKT cell dysfunction in
the illness and the need to assess cytotoxic granules in
these cells. Cytotoxic granules have not previously been
assessed in gamma delta (γδ) or regulatory T cells (Tregs)Table 1 Participant characteristics and comparisons of the age (mea
(control, moderate and severe)
Parameter Control (n = 18) M
Age in years (Mean ± SEM) 40.39 ± 2.65 4
Gender Female, Male 12, 6 1
Age data is represented as Mean ± SEM in control (n = 18), moderate CFS/ME (n = 1
There were no significant differences in age or gender within the research groups.
the meanin CFS/ME patients, which may be cells of interest accord-
ing to differences found in these cell types in previous re-
search [10, 16, 17, 34].
Previous research has outlined the presence of NK cell
dysfunction and immunological abnormalities in CFS/
ME patients although most studies only assessed moder-
ately affected CFS/ME patients. Immune dysregulation
can also be associated with the clinical features and aeti-
ology of CFS/ME. This is supported as research has
found significant clinical improvements in CFS/ME pa-
tients’ symptoms after B cell depletion [35]. It is also
possible that further immune cells may be affected by
the illness and have yet to be assessed in CFS/ME pa-
tients. The current investigation was the first to measure
the functional activity of DCs, neutrophils and mono-
cytes, lytic proteins in iNKT, γδ and Tregs as well as re-
ceptors and adhesion molecules of NK, T and B cells in
moderate and severe CFS/ME patients.Results
No differences in participant characteristics between
groups
Principal participant results are reported in Table 1. We
found no statistical difference for age or gender between
participant groups (p = 0.325, 0.607 respectively) (Table 1)
and the Fukuda criteria for CFS/ME were satisfied by all
moderate and severe CFS/ME participants.Severity scale scores differ between participant groups
In all severity scales used, including the Fatigue Severity
Scale (FSS), Dr Bell’s Disability Scale, the FibroFatigue
Scale and the Karnofsky Performance Scale (KPS), there
were significantly different scores between all participant
groups, with the exception of ‘sadness’ (p = 0.064). Mod-
erate CFS/ME patient scores were significantly worsened
compared with healthy controls in all parameters. Severe
CFS/ME patients also displayed significantly worsened
scores when compared with healthy controls, with the
exception of ‘sadness’ (p = 0.194) and ‘sleep’ (p = 0.091).
The KPS and Dr Bell’s Disability Scale scores were sig-
nificantly lower in the severe CFS/ME patients com-
pared with the moderate CFS/ME patients (p = 0.001
and 0.001).n ± SEM) and gender distribution of each participant group
oderate (n = 15) Severe (n = 12) p value
5.93 ± 2.96 41.25 ± 2.77 0.325
1, 4 10, 2 0.607
5) and severe CFS/ME (n = 12). *signifies p <0.05 between participant groups.
CFS/ME Chronic Fatigue Syndrome/Myalgic Encephalomyelitis; standard error of
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between participant groups
Our data have shown a significantly increased monocyte
count in the moderate CFS/ME patients compared with
the healthy controls and severe CFS/ME patients (Fig. 1).
There were no other statistically significant differences
in the routine full blood count parameters between the
participant groups (data not shown).
No differences in flow cytometric analysis of DC, neutrophil
and monocyte function or lytic proteins
Previous research has reported differences in DC pheno-
types in moderate and severe CFS/ME patients [5], how-
ever, this was the first research to assess DC activity in
the illness. Our data have found no significant differ-
ences in the DC activity markers CD80 and CD86, in
unstimulated or stimulated DCs between any of the par-
ticipant groups, see Additional file 1: Figure S1. Neutrophil
and monocyte function were examined as neutrophil
respiratory burst has previously been reduced in mod-
erate CFS/ME patients [8]. There were no significant
alterations between any of the participant groups in the
ability of neutrophils or monocytes to phagocytose or
undergo respiratory burst, see Additional file 2: Figure S2.
iNKT, γδT cells and Tregs have previously shown dysfunc-
tion in CFS/ME patients [5], however no studies had ex-
amined lytic proteins in these cell types. We found no
significant differences in iNKT, γδT cells or Treg levels
of perforin, granzyme A, granzyme B or CD57, see
Additional file 3: Figure S3.
NK cell adhesion molecules and natural cytotoxicity
receptors differ between moderate and severe CFS/ME
patients
Previous investigations have shown significant differences
in NK cell receptors in CFS/ME patients, however signal-
ing lymphocytic activation molecule (SLAM) receptors,
adhesion molecules and natural cytotoxicity receptorsFig. 1 Monocyte full blood counts for controls, moderate and severe CFS/M
blood counts are shown for controls, moderate and severe CFS/ME patient
significantly different where p <0.05. CFS/ME: Chronic Fatigue Syndrome/Mhave not been reported and are critical for NK cell func-
tion [5, 10]. SLAM receptor (CD150) was significantly in-
creased in our data in total NK cells of moderate CFS/ME
patients compared with severe CFS/ME patients (p =
0.046). CD56brightCD16dim NK cells expression of NKp46
was significantly reduced in severe CFS/ME compared
with controls and moderate CFS/ME (p = 0.021 and 0.021
respectively) (Fig. 2). CD56dimCD16− NK cell CD2 ex-
pression was significantly lower in moderate CFS/ME
compared with severe CFS/ME patients (p = 0.033)
while CD18+CD2− was increased in moderate CFS/ME
patients compared with controls and severe CFS/ME
in CD56dimCD16− NK cells (p = 0.009 and 0.035 re-
spectively). In the CD56dimCD16− NK cells phenotype,
CD18+CD11c− was significantly increased in the severe
CFS/ME compared with controls (p = 0.036) (Fig. 2)
(Table 2).
No differences in Bregs and BCRs
Significant B cell phenotypes have been reported in both
moderate and severe CFS/ME patients [5], however,
regulatory B (Breg) cells and B cell receptors (BCRs) in
CFS/ME cohorts are yet to be examined [5, 35]. We
found no significant differences in Breg cell phenotypes
or BCRs between the participant groups, see Additional
file 4: Figure S4.
Increased KIR2DL5 in CD4+T cells of moderate CFS/ME
patients
Killer immunoglobulin-like receptor (KIR)s have previ-
ously shown significant differences in NK cells of CFS/
ME patients, although these had not been examined in
CD4+T or CD8+T cells in CFS/ME patients [5, 7]. Our
data found no significant alterations in the expression of
KIRs on CD8+T cells between the participant groups.
KIR2DL5 expression was significantly higher on CD4+T
cells in moderate CFS/ME compared with severe CFS/
ME patients (p = 0.011) (Fig. 3) (Table 2).E participants. Monocyte numbers (x109/L) obtained from routine full
s. Data is represented as mean ± SEM. *represents results that were
yalgic Encephalomyelitis; SEM: Standard Error of the Mean
Fig. 2 The profile of receptors and adhesion molecules on isolated NK cells in controls, moderate and severe CFS/ME participants. a Profile of CD2+,
CD18+CD2+ and CD18+CD11c− adhesion molecules on CD56dimCD16− NK cells in control, moderate and severe CFS/ME patients. b CD56brightCD16dim
NK cell expression in control, moderate and severe CFS/ME patients, represented as percentage of NK cells. c Total NK cells expressing the SLAM
receptor in control, moderate CFS/ME and severe CFS/ME patients. All data are represented as percentage of total NK cells (%) and shown as mean ±
SEM. *represents results that were significantly different where p <0.05. NK: natural killer; CFS/ME: Chronic Fatigue Syndrome/Myalgic Encephalomyelitis;
SLAM: signalling lymphocyte activation molecule; SEM: Standard Error of the Mean
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between CFS/ME patient groups
CD8+T cells have been significantly different in CFS/ME
patients in previous investigations, however, receptors
on CD8+T and CD4+T cells had not yet been examined
[6, 11, 25]. We found that the CD45RA effector memory
CD8+T cell phenotype formed a significantly higher
percentage of total CD8+T cells in moderate CFS/ME
compared with controls (p = 0.016) (Fig. 4). Central mem-
ory CD8+T cells had significantly reduced lymphocyte
function-associated antigen (LFA) -1 in moderate CFS/ME
compared with controls (p = 0.032). Total CD8+T cell
expression of killer cell lectin-like receptor subfamily G
member (KLRG)1 was also reduced in moderate CFS/ME
compared with controls (p = 0.014) (Fig. 4).In our data, CD4+ central memory T cells, B and T
lymphocyte attenuator (BTLA)4 had significantly in-
creased expression in moderate CFS/ME patients com-
pared with controls (p = 0.038) (Fig. 3). KLRG1 was also
significantly reduced in CD4+ naïve T cells in moderate
CFS/ME compared with controls and severe CFS/ME
(p = 0.013 and 0.019 respectively) (Table 2). There was
no significant difference in CD4+T cell phenotypes be-
tween any of the participant groups, see Additional file 5:
Figure S5.
Correlations across severity and immune parameters
Our data showed a significantly positive correlation be-
tween the KPS and Dr Bell’s Disability Scale scores. Both
the KPS and Dr Bell’s Disability scale were negatively
Table 2 Summary of significant differences in parameters found between groups
Significant Parameters Group Potential Result of Changes
NK cell ↓ CD56dimCD16− CD2+ M v S Impaired ability to adhere to target cells [24].
↓ CD56dimCD16− CD18+CD2+ M v S Reduced NK cells in an active state hence lessened NK cell
activation and cytotoxic activity [24, 55].
↑ CD56dimCD16− CD18+CD11c− S v C Decreased adhesive abilities or lower number of activated cells [55].
↓ CD56brightCD16dim NKp46 S v C, S v M Reduced recognition and lysis of target cells [41].
↓ Total SLAM S v M Lessened ability of NK cells to undergo cytotoxic activity [40].
CD4+ T cell ↑ Total KIR2DL5 M v S Inhibition of T cell functions [51].
↓ Naïve KLRG1 M v C, M v S Enhanced T cell activation [46].
↑ Central Memory BTLA4 M v C Greater inhibitory signalling and modulation of immune responses [52].
CD8+ T cell ↑ CD45RA Effector Memory M v C Heightened capacity for cytotoxic activities [43].
↓ Central Memory LFA-1 M v C Lack of LFA-1 adhesion required for optimal cytotoxic activity [53].
↓ Total KLRG1 M v C Enhanced T cell activation [46].
↓ represents significant reductions and ↑ represents significant increases in the group listed first in the ‘Group’ column compared with the group listed second in
the ‘Group’ column. S Severe CFS/ME patients; M Moderate CFS/ME patients; C Controls
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ory phenotype values and CD56dimCD16− NK cells with
CD18+CD11c− (Table 3). There were also a number of pa-
rameters that were correlated with one another, such as
CD4+T and CD8+T cell markers, NK cell adhesion
markers and γδ and CD8+T cell phenotypes (Table 3).
Discussion
This study is the first to provide an overview of cell
function and receptor interactions, including assessing
DC, neutrophil and monocyte function and receptors on
T cells, BCRs and Bregs in moderate and severe CFS/
ME patients. This is also the first study to examine lytic
proteins in γδT cells, iNKT cells and Tregs in CFS/ME
patients. Our results suggest that in some cases, func-
tional immunological impairment may be related to dif-
ferences in severity of CFS/ME patients, highlighting the
variation in the illness. Significant alterations shown in
moderate CFS/ME patients were often not present in se-
vere CFS/ME patients and controls, revealing the possibil-
ity that moderate CFS/ME patients may have a different
aetiology compared with the severely affected subgroup of
CFS/ME patients.
Increased SLAM expression on total NK cells in mod-
erate CFS/ME patients in this study may be a mechanis-
tic response to the typically reduced NK cell cytotoxic
activity in CFS/ME [10, 11, 36]. SLAM is a receptor
expressed on the surface of T, B, NK and DC cells, func-
tioning as an activating adaptor protein to amplify the
recruitment of inflammatory cells, such as DCs, by acti-
vating IFN-γ [37-39]. SLAM receptors regulate NK cell
activity via association with SLAM associated protein
(SAP) family adapters, where binding receptors are then
coupled to the Src kinase FynT to evoke protein tyrosine
phosphorylation signals [40]. Heightened expression of
SLAM in moderate CFS/ME may enhance the ability ofNK cells to undergo cytotoxic activities [5, 7-11]. The
activating receptor NKp46 is also typically involved in
the recognition and lysis of target cells and was reduced
in CD56brightCD16dim NK cells of severe CFS/ME patients
[41]. NKp46 is highly expressed on the CD56brightCD16dim
NK cell subset and although it is only weakly involved in
cytotoxic activation, this reduction may contribute to the
reduced NK cell cytotoxic activity prevalent in severe
CFS/ME patients [5, 41, 42]. The expression of SLAM and
NKp46 on NK cells significantly differed between moder-
ate and severe CFS/ME patients, suggesting that perhaps
these severity subgroups may vary in immunological pres-
entation, as proposed by previous studies [5, 7, 13].
Effector memory and CD45RA effector memory cells
demonstrate NK-like functions as they have the ability to
detect abnormal major histocompatibility complex (MHC)
expression and have a high capability for cytotoxic ac-
tivities [43]. Our findings suggest that the number of
CD45RA effector memory CD8+T cells of moderate CFS/
ME patients may be enhanced due to sub-optimal func-
tion. In T cells, CD45RA effector memory cells are upreg-
ulated following cytokine directed proliferation, indicating
that the subset is generated via homeostasis rather than
antigen-dependent pathways [44, 45]. Moderate CFS/ME
patients have an increased number of CD8+T CD45RA ef-
fector memory cells, potentially as a result of homeostasis
where the cells may not be effectively undergoing de-
granulation and apoptosis [44, 45].
This research also found reductions in KLRG1 expres-
sion in total CD8+T and naïve CD4+T cells of moderate
CFS/ME patients, which suggests that these cells may have
a reduced ability to inhibit T cell function and activation.
KLRG1 ligation inhibits the nuclear factor of activated T
cells (NFAT) signalling pathway and downregulates CD95
mediated lysis to inhibit the activation of T cells [46].
Hence, blockades of inhibitory receptors tend to improve
Fig. 3 KIR and receptor expression in CD4+T cells of controls, moderate
and severe CFS/ME participants. a KIR2DL5 expression in total CD4+T
cells as represented by a percentage of total CD4+T cells (%). b Number
of naïve CD4+T cells expressing KLRG1 in in control, moderate and
severe CFS/ME participants shown as a number of cells per microliter
(cells/μL). C BTLA4 receptor expression in central memory CD4+T cells
of control, moderate and severe CFS/ME patients, presented as cells/μL.
Data is represented as mean ± SEM. *represents results that were
significantly different where p <0.05. KIR: killer immunoglobulin-like
receptor; CFS/ME: Chronic Fatigue Syndrome/Myalgic Encephalomyelitis;
KLRG1: killer cell lectin-like receptor subfamily G member 1; BTLA4: B
and T lymphocyte attenuator SEM: Standard Error of the Mean
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[47]. It is therefore possible that reduced KLRG1 may be
contributing to the pro-inflammatory response and T cell
activation often found in CFS/ME patients [10, 48].
Increased KIR2DL5 on CD4+T cells in moderate CFS/
ME patients may also be associated with alterations in KIR
receptors in T cells in the same cohort [5, 7]. KIR2DL5 is
an inhibitory KIR found in variable proportions of cir-
culating T cells [49, 50] which is directly linked to a
greater number of random combinations of KIR recep-
tors expressed on these cells, which may be influencing
optimal T cell functions in the illness [51]. Enhanced
inhibitory signalling and modulation of immune re-
sponses are typical attributes of increased BTLA ex-
pression in T cells which may be present in moderate
CFS/ME patients who have amplified expression of in-
hibitory receptor BTLA4 in central memory CD4+T
cells [52]. Activation and function of CD4+T cells by
NK cells is dependent on the engagement of the β2 in-
tegrin LFA-1. LFA-1 adhesion is necessary for optimal
cytotoxic activity by both NK cells and CD8+T cells,
also mediating NK cell degranulation via synergy with
NKG2D [53]. Decreased expression of LFA-1 on central
memory CD8+T cells in moderate CFS/ME patients
suggests that there may be a lack of LFA-1 adhesion in
CFS/ME which is required for ideal cytotoxic activity
by NK cells and CD8+T cells [53]. Similar to the pattern
shown in SLAM and NKp46 receptors on NK cells,
CD45RA effector memory CD8+T cells and CD4+T and
CD8+T cell receptors significantly differed between
moderate and severe CFS/ME patients.
Cellular adhesion may be important in CFS/ME as it is
required for target cell contact and NK cell effector
function. Regulation of adhesion molecules is necessary
for integrin target cell ligand interactions as the release
of adherence results in lymphocyte movement [54]. CD2
expression in CD56dimCD16− NK cells is reduced in
moderate CFS/ME patients compared with severely af-
fected patients, suggesting that these cells may have an
impaired ability to adhere to target cells. This confirmed
previous findings where CD2/CD18 co-expression was
reduced in the same CD56dimCD16− NK cell phenotype
Fig. 4 Alterations in peripheral blood CD8+T cell phenotypes and receptors in controls, moderate and severe CFS/ME. a CD45RA effector memory,
naïve, central memory and effector memory CD8+T cell phenotypes represented as percentage of total CD8+T cells (%). b LFA-1 expression in central
memory CD8+T cells for control, moderate CFS/ME and severe CFS/ME participants. c KLRG1 expression in total CD8+T cells for control, moderate CFS/
ME and severe CFS/ME participants. All data are represented as mean ± SEM. * represents results that were significantly different where p <0.05. CFS/
ME: Chronic Fatigue Syndrome/Myalgic Encephalomyelitis; LFA-1: lymphocyte function-associated antigen 1; KLRG1: killer cell lectin-like receptor
subfamily G member 1; SEM: Standard Error of the Mean
Table 3 Spearman’s correlation to identify correlates between significant parameters
1 2 3 4 5 6 7 8 9 10 11 12 13 14
1 CM CD8+ LFA-1
2 Naïve CD4+ KLRG1
3 Total CD8+ KLRG1 .50
4 CM CD4+ BTLA4 .55
5 CM CD4+ LFA-1 .56
6 CD56dimCD16− NK CD2+
7 CD56dimCD16− NK CD18+CD2+ -.60
8 CD56dimCD16− NK CD18+CD11a− -.47 .49 -.57
9 CD56dimCD16− NK CD18+CD11c−
10 Total NK SLAM .46 -.53 -.50
11 Total CD8+ EMRA -.44 -.75
12 CD4+ KIR2DL5 .48 .75
13 KPS -.43
14 Dr Bell’s Disability Scale -.46 .95
Table 3 shows the significant correlation values between bivariate parameters for significant parameters for combined control, moderate CFS/ME and severe CFS/
ME participant groups. All correlations shown have p < 0.01. CM: Central Memory, EMRA: CD45RA Effector Memory
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CD2 is often associated with a higher cytotoxic ability
[55] as CD2 acts as a contributor to induce NK cell acti-
vation [54, 55]. Higher expression of CD2 in severe CFS/
ME patients potentially implies that more NK cells in
these patients are in an active state and may have a
greater ability than the moderate CFS/ME patients to in-
duce NK cell activation and cytotoxic activities [55].
CD18+/CD2− CD56dimCD16− NK cells were also in-
creased in the moderate CFS/ME patients, strengthening
the theory that CFS/ME patients may have a weakened
ability to activate NK cells as well as having impaired
NK cell cytotoxic activity. Adhesion molecules CD18
and CD2 on CD56dimCD16− NK cells were also signifi-
cantly altered in the moderate CFS/ME patient group
compared with the severe CFS/ME patients, who appeared
similar to the controls. In the case of CD18+CD11c− on
the same CD56dimCD16− NK cell subset, however, in-
creases in CD18+CD11c− increased in the moderate CFS/
ME patients and significantly increased in the severe
CFS/ME patients. Expression of the adhesion marker
CD11c is heterogeneous and variable in NK cells al-
though, typically activated NK cells are CD11c+ [55].
Increased CD18+CD11c− on CD56dimCD16− NK cells in
severe CFS/ME patients indicates that these patients may
have a reduced ability to adhere or that they may have a
low number of activated NK cells. Therefore, differences
in CD18+CD11c− adhesion molecules in severe CFS/ME
patients may be associated with the reduced NK cell cyto-
toxic activity found in the illness [5, 10, 11].
CFS/ME symptom severity and presentation may be
related to the immune dysregulation shown as the im-
mune system interacts with physiological functioning via
a number of body systems, including the central nervous
system, digestive system and endocrine system [56].
Unrefreshing sleep and sleep disturbances are symptoms
of CFS/ME and reports have indicated that NK cells are
altered after sleep deprivation, demonstrating interac-
tions between physiological symptoms and the immune
system [57], particularly in CFS/ME patients. Similarly, it
has previously been suggested that clinical severity status
appears to be associated with reduced NK cell activity in
CFS/ME patients [7, 13]. Although there are limited re-
search findings for severe CFS/ME patients, the differ-
ences in NK cells, CD4+T and CD8+T cells between
severity groups, found in this research, suggest that im-
mune dysfunction in CFS/ME may be related to clinical
symptoms and hence severity.
Conclusions
This study was the first to show significant differences in
a number of receptors in NK, CD4+T and CD8+T cells
in CFS/ME [5, 7] suggesting dysregulation in NK cell
cytotoxic activity, receptor regulation and potentially celladherence. Consistent with previous literature, our re-
search suggests that CFS/ME patients have immunological
dysregulation in the innate and adaptive immune cells.
We have also highlighted significant differences in NK,
CD4+T and CD8+T cells between moderate and severe
CFS/ME patients, suggesting severity subgroups may have
distinct immune perturbations and consequently aeti-
ology. Further studies examining severity subgroups of
CFS/ME patients may therefore contribute to the un-




Participants aged between 20 and 65 years old were re-
cruited from Queensland and New South Wales areas of
Australia through CFS/ME support groups, email adver-
tisements and social media. In the absence of a diagnos-
tic test for CFS/ME, the 1994 Fukuda criteria were used
and patients must have had the illness for a period of at
least 6 months prior to the study. All CFS/ME patients
had been diagnosed by a primary physician in order to
take part in the research. CFS/ME patients were identi-
fied as either moderate (mobile) or severe (housebound).
These severity groups were then confirmed using an
extensive questionnaire which included FSS, Dr Bell’s
Disability Scale, the FibroFatigue Scale and the KPS as de-
terminants of severity. Participants were then excluded if
they were previously diagnosed or had a history of an
autoimmune disorder, MS, psychosis, major depression,
heart disease or thyroid-related disorders or if they were
pregnant, breast feeding, smokers, or experiencing symp-
toms of CFS/ME that did not conform to the Fukuda cri-
teria for CFS/ME [5]. The questionnaire obtained detailed
information regarding the onset of illness, presence, fre-
quency and severity of symptoms, comorbidities, overall
health and quality of life. This allowed an analysis of all
participants on an individual basis to ensure there were
no confounding factors influencing CFS/ME patient
symptoms. In order to identify psychological exclu-
sions in participants that were not specifically outlined,
the questionnaire (including the FSS, SF-36 and WHO
DAS2.0) also included questions and scales regarding
emotional stability, social interaction, motivation and
wellbeing [58, 59].
Participants (n = 45) included in the study were pa-
tients moderately (n = 15) or severely (n = 12) affected by
CFS/ME symptoms as well as a healthy non-fatigued con-
trol group (n = 18). All participant groups were matched
for age and sex. All CFS/ME patients had the illness for at
least 6 months prior to their participation in the research
and the average duration of illness of a CFS/ME patient
was 6.5 years. It was then ensured that all participating
CFS/ME patients fulfilled the Fukuda criteria for CFS/ME
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which assessed their symptoms in the 30 days prior and at
the time of collection. Written informed consent was ob-
tained from all participants and all research protocols were
granted ethical clearance after review by the Griffith Uni-
versity Human Research Ethics Committee (GU Ref No:
MSC/23/12/HREC).
Sample preparation and routine measures
Blood collection occurred between 8:00 and 11:30 am
and samples were analysed within 12 h. A non-fasting
blood sample of 50 mL was collected into lithium hepar-
inised and ethylenediaminetetraacetic acid (EDTA) tubes
from the antecubital vein of all participants. Initial full
blood count results were determined by Pathology
Queensland to assess routine levels of white blood cell
and red blood cell markers.
Lytic proteins analysis
Lytic proteins were assessed as previously described [7,
10] in Tregs, iNKT, γδ1 and γδ2 T cells. Ficoll-hypaque
(Sigma, St Louis, MO) density gradient centrifugation
was used to isolate peripheral blood mononuclear cells
(PBMCs) from EDTA whole blood. PBMCs were adjusted
to 1 × 107 cells/mL and stained with monoclonal anti-
bodies for iNKT, Tregs, γδ1 and γδ2 T cells, see Additional
file 6: Table S1. Cells were incubated for 30 min in Cytofix
then perforin, granzyme A and granzyme B monoclonal
antibodies were added for 30 min. Cells were analysed on
the flow cytometer where perforin, granzyme A and gran-
zyme B expression was measured in iNKT, Tregs, γδ1 and
γδ2 T cells, see Additional file 6: Table S1.
DC cell activity analysis
DC activity was measured from 300uL lithium heparinised
whole blood, incubated in Roswell Park Memorial Insti-
tute (RPMI)-1640 culture media (Invitrogen, Carlsbad,
CA), Phorbol 12-myristate 13-acetate (PMA) and Ionomy-
cin for 5 h at 37 °C, 5 % CO2. Cells were labelled with
monoclonal antibodies (see Additional file 6: Table S1)
and FACS Lyse (BD Biosciences, San Diego, CA) was
used to remove red blood cells. Flow cytometric analysis
(Becton Dickinson Immunocytometry Systems) was used
to measure DC activity based on unstimulated versus
stimulated assessments.
Phagocytosis analysis
The Phagotest kit was used to determine leukocyte phago-
cytosis in whole blood based on the ability of neutro-
phils and monocytes to engulf bacteria (Orpegen Pharma,
Germany). Manufacturer’s instructions were followed for
the procedure. Lithium heparinised whole blood (100uL)
was aliquot into two 5 mL tubes as control and test sam-
ples. Control and test samples were incubated with E.colibacteria (Orpegen Pharma, Germany) on ice or at 37 °C
respectively, before quenching solution were added to
stop phagocytosis. Samples were washed and red blood
cells were lysed with lysing solution (Orpegen Pharma,
Germany). DNA staining solution was used as a meas-
ure of neutrophil and monocyte phagocytosis based on
differential gating on a flow cytometric analysis (Becton
Dickinson Immunocytometry Systems).
Respiratory burst analysis
Respiratory burst analysis was measured in granulocytes
from whole blood. Intracellular oxidation was performed
by incubating 100uL lithium heparinised whole blood in
Dihydrohodamine (DHR) for 10 min at 37 °C. Phorbol
12-myristate 13-acetate was then added, followed by
10 min incubation at 37 °C. FACS Lyse (BD Biosciences,
San Diego, CA) was used to remove red blood cells and
DHR was used as a measure of neutrophil and monocyte
respiratory burst using differential gating on the flow cyt-
ometer (Becton Dickinson Immunocytometry Systems).
Isolated NK cell receptor analysis
As previously described [5], NK cells were isolated from
whole blood cells using negative selection with RosetteSep
Human Natural Killer Cell Enrichment Cocktail (StemCell
Technologies, Vancouver, BC). Isolated NK cells were
labelled with CD56, CD16, CD3 (BD Biosciences, San
Diego, CA) and monoclonal antibodies for SLAM, in-
tegrin and natural cytotoxicity receptors (NCRs), see
Additional file 6: Table S1 (Miltenyi Biotec). Analysis was
undertaken on the flow cytometer (Becton Dickinson
Immunocytometry Systems), where NK cells were gated
using CD56, CD16 and CD3 and SLAM, integrin and NCR
receptors were assessed for each NK cell phenotype
(CD56dimCD16+, CD56brightCD16+, CD56dimCD16− and
CD56brightCD16dim) see Additional file 6: Table S1 [7].
T and B cell whole blood analysis
Whole blood analysis was undertaken as previously de-
scribed [5]. Monoclonal antibodies were added to lith-
ium heparinised whole blood samples and incubated for
30 min, see Additional file 6: Table S1. Cells were then
lysed, washed and fixed. CD4+T and CD8+T cell KIR re-
ceptors and phenotypes, B cell receptors and B regula-
tory cells were assessed using appropriate antibodies
(see Additional file 6: Table S1) and gating strategies on
the flow cytometer (Becton Dickinson Immunocytome-
try Systems) [60].
Statistical analysis
Data were compared among the three participant groups
(control, moderate CFS/ME and severe CFS/ME) with
statistical analysis performed based on the distribution.
Shapiro-Wilk normality tests were performed and if
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was used. If data was not normally distributed, the Kruskal
Wallis test of independent variables based on rank sums
to determine the magnitudes of group differences was
used. The Bonferroni Post Hoc or Mann–Whitney U tests
determined p values of significance for parametric and
non-parametric data respectively, with statistical sig-
nificance set at an alpha criterion at p < 0.05. Spearman’s
non-parametric correlation was conducted on significant
parameters to determine correlates where significance was
accepted as p < 0.01. Outliers were identified using a box-
plot technique and handled by eliminating particular ex-
treme data points from the analysis [61].
SPSS statistical software version 22.0 was used for all
statistical analysis and data represented in this study are
reported as plus/minus the standard error of the mean
(±SEM) or plus/minus the standard deviation (SD) as
specified.Additional files
Additional file 1: Figure S1. Flow cytometric analysis of dendritic cell
activity in controls, moderate and severe CFS/ME patients using CD80
and CD86 activation markers. DC activity is shown based on the difference
in expression of activation markers (CD80 and CD86) following stimulation.
Measures are represented as percentage of DCs expressing markers (%) in
controls, moderate CFS/ME and severe CFS/ME. All data are represented as
mean ± SEM. CFS/ME: Chronic Fatigue Syndrome/Myalgic Encephalomyelitis;
DC: Dendritic Cell. SEM: Standard Error of the Mean.
Additional file 2: Figure S2. Flow cytometric analysis of monocyte
and neutrophil function in controls, moderate and severe CFS/ME
patients. A Monocyte and Neutrophil function respiratory burst, shown as
difference in mean fluorescence intensity following stimulation. Measures
are shown for controls, moderate CFS/ME and severe CFS/ME. B Monocyte
and Neutrophil function phagocytosis, shown as difference in mean
fluorescence intensity following stimulation. Measures are shown for
controls, moderate CFS/ME and severe CFS/ME. CFS/ME: Chronic Fatigue
Syndrome/Myalgic Encephalomyelitis.
Additional file 3: Figure S3. Intracellular analysis of lytic proteins in
controls, moderate and severe CFS/ME patients. A Lytic proteins in iNKT
cells are shown as percentage of iNKT cells (%) expressing perforin,
granzyme A, granzyme B and CD57 for controls, moderate CFS/ME and
severe CFS/ME patients. B Lytic proteins in Tregs are shown as
percentage of Tregs (%) expressing the lytic proteins perforin, granzyme
A, granzyme B and CD57 in controls, moderate CFS/ME and severe CFS/
ME patients. All data are represented as mean ± SEM. Chronic Fatigue
Syndrome/Myalgic Encephalomyelitis; Treg: T Regulatory Cell. SEM:
Standard Error of the Mean.
Additional file 4: Figure S4. Profile of Bregs and BCRs in controls,
moderate and severe CFS/ME patients. A Bregs are as percentage of
B cells (%) in controls, moderate CFS/ME and severe CFS/ME patients.
B CD79b and IgD expression to represent BCRs and shown as a
percentage of B. BCRs shown in controls, moderate CFS/ME and
severe CFS/ME patients. All data are represented as mean ± SEM.
Breg: B Regulatory Cell; BCR: B Cell Receptor; Chronic Fatigue Syndrome/
Myalgic Encephalomyelitis; Treg: T Regulatory Cell. SEM: Standard Error of
the Mean.
Additional file 5: Figure S5. Peripheral blood CD4+T cell phenotypes
in controls, moderate and severe CFS/ME patients. CD45RA effector
memory, naïve, central memory and effector memory CD4+T cell
phenotypes represented as percentage of total CD4+T cells (%). All dataare represented as mean ± SEM. CFS/ME: Chronic Fatigue Syndrome/
Myalgic Encephalomyelitis; SEM: Standard Error of the Mean.
Additional file 6: Table S1. Monoclonal antibody combinations used
to identify various innate and adaptive immune cells and phenotypes.
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